159 related articles for article (PubMed ID: 35399948)
1. Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report.
Fu Y; Liu J; Jiang Y
Front Endocrinol (Lausanne); 2022; 13():810747. PubMed ID: 35399948
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.
Li Y; Liu Y; Qu Y; Chen X; Qu X; Ye Y; Du X; Cheng Y; Xu M; Zhang H
Front Immunol; 2022; 13():832593. PubMed ID: 35603147
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
Sun C; Ma X; Jiang L; Zhu X
Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
[TBL] [Abstract][Full Text] [Related]
4. A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma.
Zou J; Yang X; Duan J; Wang J; Yang Z; Luo D; Liu L; Chen J; Nie J
Onco Targets Ther; 2021; 14():4599-4607. PubMed ID: 34475766
[TBL] [Abstract][Full Text] [Related]
5. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
6. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
8. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
9. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review.
Cheng K; Liu X; Chen Y; Zhou K; Li Z
BMC Gastroenterol; 2022 Aug; 22(1):388. PubMed ID: 35978277
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
Jiang Y; Zhang L; Zhu F; Zhu H; Cao X; Zhang Y
Ann Palliat Med; 2022 Mar; 11(3):1135-1146. PubMed ID: 35365044
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of advanced ovarian cancer with anlotinib: a case report.
Zhang P; Ma L; Wang X; Zhang R; Dong Y
J Int Med Res; 2020 Dec; 48(12):300060520976824. PubMed ID: 33284728
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure.
Zan N; Zhang X; Du L; Lin Z; Yu D; Liu J; Gou F
Front Oncol; 2022; 12():796407. PubMed ID: 35296012
[TBL] [Abstract][Full Text] [Related]
13. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
14. Combination anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report.
Liu L; Chen B; Tang M; Guo Y; Hou J; Zhou W; Zhu X
Anticancer Drugs; 2024 May; ():. PubMed ID: 38728054
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
16. [Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib].
Huang L; Qin Y; Zhao F; Zhou S; Shi Y
Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):739-742. PubMed ID: 34628779
[TBL] [Abstract][Full Text] [Related]
17. Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review.
Salemis NS
Breast Dis; 2018; 37(3):169-175. PubMed ID: 29504519
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report.
Chen SC; Ma DH; Zhong JJ
World J Clin Cases; 2023 Sep; 11(27):6579-6586. PubMed ID: 37900244
[TBL] [Abstract][Full Text] [Related]
19. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
[TBL] [Abstract][Full Text] [Related]
20. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review.
Niu G; Wang H; Ren Y; Xing X; Zhao L; Liu N; Wen X; Zhai Y
Immunotherapy; 2023 Aug; 15(12):905-912. PubMed ID: 37340883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
